|
PHRF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.31869999983903E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.31429999999477E-05 |
| Normal-vs-Stage2 |
4.007700E-04 |
| Normal-vs-Stage3 |
8.58469999531764E-08 |
| Normal-vs-Stage4 |
3.34339999996658E-06 |
| Stage1-vs-Stage2 |
6.125000E-01 |
| Stage1-vs-Stage3 |
4.090200E-02 |
| Stage1-vs-Stage4 |
2.173600E-01 |
| Stage2-vs-Stage3 |
3.798400E-01 |
| Stage2-vs-Stage4 |
5.988000E-01 |
| Stage3-vs-Stage4 |
7.591800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.26859999960827E-07 |
| Normal-vs-AfricanAmerican |
1.939940E-02 |
| Normal-vs-Asian |
2.516100E-02 |
| Caucasian-vs-AfricanAmerican |
3.945400E-01 |
| Caucasian-vs-Asian |
6.804400E-02 |
| AfricanAmerican-vs-Asian |
6.730600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.73289999999749E-06 |
| Normal-vs-Female |
7.71029999957484E-07 |
| Male-vs-Female |
7.034400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.182920E-04 |
| Normal-vs-Age(41-60Yrs) |
2.49269999996748E-06 |
| Normal-vs-Age(61-80Yrs) |
9.39840000269143E-08 |
| Normal-vs-Age(81-100Yrs) |
3.756600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.277600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.655700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.418000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.372600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.964000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.254200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.033700E-04 |
| Classical-VS-Follicular |
1.171690E-04 |
| Classical-VS-Other |
5.568800E-01 |
| Classical-VS-Normal |
1.635950E-04 |
| Tall-VS-Follicular |
5.284600E-01 |
| Tall-VS-Other |
1.897230E-01 |
| Tall-VS-Normal |
9.35300004112349E-09 |
| Follicular-VS-Other |
4.500800E-01 |
| Follicular-VS-Normal |
1.57220000351899E-08 |
| Other-VS-Normal |
3.403500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.29750000030538E-07 |
| Normal-vs-N1 |
1.36900000002882E-06 |
| N0-vs-N1 |
5.270200E-01 |
|
|
